Search results for " vaccines"
Article
High-Throughput Process Development in an Historical Environment
Conversely, Vanessa Jully from Université Catholique de Louvain in Brussels, Belgium, presented a different conclusion based on her collaboration with GlaxoSmithKline Vaccines, in which a high-through…
Article
Single-Use Technologies Prove Effective for Viral Vector Process Development
“The simple reality is that the COVID-19 pandemic has shown the benefits of single-use systems in that it would not have been possible to deploy the viral vaccines in the time and the scale that has b…
Article
Single-use Bioreactors Have Reached the Big Time
“Examples include traditional vaccines and blockbuster [monoclonal antibody] (mAb) biologics (>2 metric tons of mAb per year); in these cases, single-use bioreactors might not be the most efficient pr…
Article
Modular Manufacturing Platforms for Biologics
G-CON Manufacturing, “G-CON Manufacturing Announces Delivery and Operation of a Custom Made POD for PaxVax, Developer of Oral Vaccines for Infectious Diseases,” Press Release, Jan. 18, 2013.
8. J.…
Article
Track-and-Trace Progress Benefits Supply-Chain Security Efforts
Since the COVID-19 pandemic struck, there has been little news of serialization breakthroughs, as manufacturers and their supply partners have focused on getting new therapeutics and vaccines to patie…
Article
Process Development: 2020 Reflections and 2021 Possibilities
Last year in particular reenforced the need to reapproach optimization and flexibility for all bioprocesses, as well as emphasized the importance of life-saving products such as vaccines.
To shed …
Article
Scalable Viral Vector Manufacturing
What are the main reasons for this rapid increase in viral vector manufacturing?
Viral vector platforms emerging at the crossroads of cell, gene therapy, and vaccines are becoming a promising ar…
Article
Achieving Efficient Adenovirus Upstream Production
Adenovirus is one of the most frequently used viral vectors in the development of therapeutic vaccines and vaccines against infectious diseases. Adenovirus has also been explored as a viral vector f…
Article
Biopharmaceutical Market in Asia: Q&A with Günter Jagschies, Strategic Customer Relations Leader, Cytiva
…biotherapeutic drugs on the high end of the price range as well as even to the much cheaper class of vaccines. Korea, Japan, and Singapore, in particular, have a well-established biopharma industry w…
Article
SEC in the Modern Downstream Purification Process
Mar 01, 2015
By R. Christopher Manzari, J. Kevin O'Donnell
BioPharm International
Volume 3, Issue 28
Since the introduction of commercial chromatography resins approximately six de…